PT  - JOURNAL ARTICLE
AU  - Eyal Mishani
AU  - Aviv Hagooly
TI  - Strategies for Molecular Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase in Cancer
AID  - 10.2967/jnumed.109.062117
DP  - 2009 Aug 01
TA  - Journal of Nuclear Medicine
PG  - 1199--1202
VI  - 50
IP  - 8
4099  - http://jnm.snmjournals.org/content/50/8/1199.short
4100  - http://jnm.snmjournals.org/content/50/8/1199.full
SO  - J Nucl Med2009 Aug 01; 50
AB  - A wealth of research has focused on developing targeted cancer therapies by specifically inhibiting epidermal growth factor receptor tyrosine kinase (EGFR-TK). However, the outcome of most EGFR-TK–targeted drugs that were approved by the Food and Drug Administration or entered clinical trials has been only moderate. Enhancement of EGFR-targeted therapy hinges on a reliable in vivo quantitative molecular imaging method. Such a method would enable monitoring of receptor drug binding and receptor occupancy in vivo; determination of the duration of EGFR inhibition in vivo; and, potentially, identification of a primary or secondary mutation in EGFR leading to drug interaction or loss of EGFR recognition by the drug. This review analyzes the most recent strategies to visualize and quantify EGFR-TK in cancer by nuclear medicine imaging and describes future directions.